黄河 He Huang

研究员，博士生导师，课题组长。工作聚焦于蛋白质新型翻译后修饰研究，一方面发现蛋白新型翻译后修饰及其关键调控因子，并结合临床资源和数据揭示其在疾病演进过程中的作用机制；另一方面，鉴定代谢调节活性天然产物分子的作用靶标，阐释其通过翻译后修饰介导表型的新机制。代表性研究成果：（1）发现蛋白新型修饰：发现了一种全新动态修饰——赖氨酸乙酰乙酰化及其调控酶HBO1，为基于表观遗传靶标的创新药物研究带来了新方向（Adv Sci, 2023）；（2）揭示蛋白新型修饰调控机制：揭示了乳酰化、β-羟基丁酰化、苯甲酰化和琥珀酰化修饰的关键调控酶，拓展了其修饰底物谱，阐释了上述新型修饰耦合乳酸、酮体等代谢物与多种细胞进程的新机制（Cell Metab, 2025；iScience, 2024；Cell Discov, 2023；Sci Adv, 2021）；（3）探索蛋白新型修饰临床转化：将新型修饰组学引入到临床研究中，系统绘制了肝癌组织乳酰化修饰全景图谱，揭示了乳酰化对肝癌细胞代谢的关键调节作用，发现了腺苷酸激酶2（AK2）可以作为潜在的治疗靶标，为肝细胞癌靶向治疗提供了新思路（Nat Metab, 2023）；（4）阐明药物作用新靶标、新机制：发现了高血脂治疗潜在新靶标HNF-1α，揭示了小檗碱类天然产物降脂药物DC371739介导转录因子和组蛋白修饰的独特表观遗传调控机制，鉴定了该药物的临床疗效监控生物标志物PCSK9和ANGPTL3（Cell Metab, 2022）。共发表SCI论文91篇，获得美国授权专利5项。其中以第一或通讯作者（含共同）在Cell、Cell Metab、Nat Metab、Mol Cell、Sci Adv、Nat Comm、J Am Chem Soc等杂志上发表论文47篇。论文总影响因子865.7，被引用10600余次。

Researcher, doctoral supervisor, and principal investigator. His work focuses on novel protein post-translational modifications research. On one hand, he discovers novel protein post-translational modifications and their key regulatory factors, and reveals their mechanistic roles in disease progression by integrating clinical resources and data; on the other hand, he identifies the action targets of metabolically active natural product molecules and elucidates novel mechanisms by which they mediate phenotypes through post-translational modifications. Representative research achievements: (1) Discovery of novel protein modifications: discovered a completely new dynamic modification – lysine acetoacetylation and its regulatory enzyme HBO1, bringing new directions for innovative drug research based on epigenetic targets (Adv Sci, 2023); (2) Revealing regulatory mechanisms of novel protein modifications: revealed key regulatory enzymes of lactylation, β-hydroxybutyrylation, benzoylation, and succinylation modifications, expanded their modification substrate spectra, and elucidated novel mechanisms by which these modifications couple metabolites such as lactate and ketone bodies with various cellular processes (Cell Metab, 2025; iScience, 2024; Cell Discov, 2023; Sci Adv, 2021); (3) Exploring clinical translation of novel protein modifications: introduced novel modification omics into clinical research, systematically mapped the landscape of lactylation modifications in liver cancer tissues, revealed the key regulatory role of lactylation in liver cancer cell metabolism, and discovered that adenylate kinase 2 (AK2) can serve as a potential therapeutic target, providing new insights for targeted therapy of hepatocellular carcinoma (Nat Metab, 2023); (4) Elucidating novel drug targets and mechanisms: discovered HNF-1α as a potential new target for hyperlipidemia treatment, revealed the unique epigenetic regulatory mechanism of the berberine-class natural product lipid-lowering drug DC371739 mediating transcription factors and histone modifications, and identified PCSK9 and ANGPTL3 as biomarkers for monitoring the clinical efficacy of this drug (Cell Metab, 2022). He has published 91 SCI papers in total and obtained 5 US patents. Among them, 47 papers were published as first or corresponding author (including co-authorship) in journals such as Cell, Cell Metab, Nat Metab, Mol Cell, Sci Adv, Nat Comm, and J Am Chem Soc. The total impact factor of his papers is 865.7, with over 10,600 citations.